AORT Earnings Prediction
The chart below shows how AORT performed 10 days before and after its earnings report, based on data from the past quarters. Typically, AORT sees a +0.14% change in stock price 10 days leading up to the earnings, and a +3.84% change 10 days following the report. On the earnings day itself, the stock moves by +0.01%. This data can give you a slight idea of what to expect for the next quarter's release.
AORT Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
97.31M
3.88%
1.60%
Gross Margin
63.20%
-3.10%
-0.78%
Operating Margin
2.74%
-54.79%
-66.30%
Net Margin
-16.94%
299.53%
608.79%
EPS
-0.42
-320.00%
740.00%
No Data Available
AORT Earnings Analysis
Artivion Inc Corporation (AORT.N) Earnings Conference Call
Positive
Constant Currency Revenue Growth: Total constant currency revenue growth of 10% excluding PerClot, indicating strong overall performance.
EBITDA Margin Expansion: Expanded EBITDA margins by 310 basis points, resulting in adjusted EBITDA growth of 32% year-over-year, showcasing operational efficiency.
Revenue Increase and Market Gains: On-X revenue increased 10% year-over-year on a constant-currency basis, reflecting market share gains and strong clinical benefits.
Stent Graft Revenue Growth: Stent graft revenues grew 8% on a constant currency basis, indicating continued demand and growth in this product category.
BioGlue Growth Prospects: BioGlue grew 7% on a constant currency basis, with regulatory approval in China expected to drive future growth.
Regional Revenue Growth: Latin America and Asia-Pacific regions delivered constant-currency revenue growth of 26% and 11% respectively, highlighting successful expansion efforts.
Humanitarian Device Exemption Impact: The Humanitarian Device Exemption (HDE) for AMDS represents a significant milestone, allowing for commercial distribution prior to PMA approval, which is expected to enhance revenue.
Clinical Benefits of AMDS Trial: Data from the AMDS PERSEVERE trial demonstrated significant clinical benefits, including a 72% reduction in mortality, reinforcing the product's potential impact.
Future Performance Expectations: Expectations for 2025 include constant currency growth of 10% to 14%, with adjusted EBITDA projected to grow 18% to 28% over 2024, indicating strong future performance.
Negative
Earnings Miss Reported: Artivion, Inc. reported a significant earnings miss with an EPS of $-0.39, falling short of expectations of $0.12.
Cyber Incident Impact on Revenue: The company faced a cyber incident that negatively impacted Q4 revenue by approximately $4.5 million, which reduced revenue growth by an estimated 5%.
Tissue Processing Revenue Decline: Tissue processing revenues declined by 8% year-over-year in Q4, indicating challenges in this segment due to the cyber incident.
Revenue Growth with Supply Challenges: Despite overall revenue growth of 3% in Q4, the company experienced a slowdown in tissue and On-X supply, which is expected to affect Q1 2025 revenues significantly.
Tissue Revenue Decline: The company anticipates that tissue revenues will be significantly lower-than-normal in Q1 2025, with a backlog expected to be cleared later in the year.
Rising Operational Costs: General, administrative, and marketing expenses increased slightly from $50.3 million in Q4 2023 to $51.4 million in Q4 2024, indicating rising operational costs.
Rising Interest Expenses: Interest expenses rose sharply to $9.4 million in Q4 2024 from $5.8 million in the prior year, reflecting increased financial burdens.
Cyber Expense Impact: The company expects to incur additional cyber-related expenses in 2025, which could further strain financial performance.
AORT FAQs
How does AORT typically perform around its earnings report dates?
Is Artivion Inc (AORT) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
AORT Earning Call Sentiment
Artivion, Inc. (NYSE:AORT) Q4 2024 Earnings Call Transcript
AORT.N
2.99%Positive
The earnings call reflects mixed signals. The company reported strong revenue and EBITDA growth, but missed EPS expectations and faced a cyber incident impacting financials. The Q&A revealed concerns about AMDS timeline delays and cybersecurity issues, with management providing vague responses. No shareholder return plan was announced, which is typically negative. The negative impact of currency fluctuations and high leverage are additional concerns. Given these factors, the sentiment leans negative, suggesting a stock price decrease of -2% to -8% over the next two weeks for this small-cap company.
